5 completed, 1 active not recruiting, 1 terminated. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 4, Active not recruiting 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Lactones: new trials by email Literature Review of Lactones trials Research Report on Lactones
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma Laboratory Biomarker Analysis, Romidepsin, Venetoclax - Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 12 | 2018-08-21 | 2023-10-19 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Alisertib, Laboratory Biomarker Analysis, Romidepsin - MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2013-07-17 | 2019-01-28 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
Lymphoma, T-Cell (6) · Lymphoma, Large-Cell, Anaplastic (4) · Lymphoma, T-Cell, Cutaneous (4) · Mycosis Fungoides (3) · Breast Neoplasms (2) · Hodgkin Disease (2) · Immunoblastic Lymphadenopathy (2) · Burkitt Lymphoma (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Enteropathy-Associated T-Cell Lymphoma (1) · Glioma (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lung Neoplasms (1)
M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · City of Hope Medical Center (1) · Mayo Clinic (1) · Walter Hanel (1)
United States (7) · Canada (1)
Grzegorz S. Nowakowski, M.D. (1) · Hun Lee (1) · Jasmine M Zain (1) · Michelle Fanale (1) · Roisin M Connolly (1) · Swaminathan P Iyer, MD (1) · Walter Hanel, MD, PhD (1)
P30CA016672 (2), P30CA033572 (1), U01CA062461 (1), U01CA062505 (1), U01CA069912 (1), U01CA070095 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186716 (1), UM1CA186717 (1)